Bluejay Therapeutics has reported the successful completion of a Phase Ia trial and enrolment of the initial Phase Ib cohorts for BJT-778, a monoclonal antibody targeting hepatitis B surface antigen.

BJT-778-001 is a double-blind, placebo-controlled single ascending dose study involving healthy volunteers and subjects with chronic hepatitis B (CHB) and chronic hepatitis D infection (CHD).

The US based company stated that BJT-778 was well tolerated, with no dose-limiting toxicities.

“We anticipate building on this success as we strive to broaden our portfolio of treatments and cures for viral and liver diseases,” said Blujay Therapeutic’s CEO Dr Keting Chu.

In August, Bluejay raised $41 million in Series B financing led by Arkin Bio Ventures.

The company has a licencing agreement with Novartis for its other CHB preclinical pipeline drug, BJT-628.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

GlobalData (GD) has identified China as an emerging innovator in the HBV therapies market, with Asia-Pacific region hosting the highest number of clinical trials in the field.

China based Jiangsu Hansoh Pharmaceutical’s Hengmu (tenofovir amibufenamide) is currently marketed in China. GD projects $732 million in sales for Hengmu in 2028.

Gilead Science’s Hepcludex (bulevirtide) is conditionally authorised in European Economic Area (EU) and the United Kingdom. However, it has not been approved by the US Food and Drug Administration (FDA).